0001593968-23-000529.txt : 20230324
0001593968-23-000529.hdr.sgml : 20230324
20230324201918
ACCESSION NUMBER: 0001593968-23-000529
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230322
FILED AS OF DATE: 20230324
DATE AS OF CHANGE: 20230324
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MOORE ALISON
CENTRAL INDEX KEY: 0001754937
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38693
FILM NUMBER: 23761247
MAIL ADDRESS:
STREET 1: C/O ALLOGENE THERAPEUTICS, INC.
STREET 2: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allogene Therapeutics, Inc.
CENTRAL INDEX KEY: 0001737287
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 823562771
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 457-2700
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
primary_01.xml
PRIMARY DOCUMENT
X0407
4
2023-03-22
0001737287
Allogene Therapeutics, Inc.
ALLO
0001754937
MOORE ALISON
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO
CA
94080
true
Chief Technical Officer
false
Common Stock
2023-03-22
4
A
false
558094
0
A
672731
D
Stock Option (Right to buy)
5.04
2023-03-22
4
A
false
432738
0
A
2033-03-22
Common Stock
432738
432738
D
Includes 429,303 of performance RSUs which shall vest as follows: (1) 33% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 67% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.
25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.
/s/Veer Bhavnagri, Attorney-in-Fact
2023-03-24